Skip to menu Skip to content Skip to footer

2024

Conference Publication

DNA methylation discriminates between responder and non-responder status in a long-term study of cladribine tablet use in multiple sclerosis

Maltby, Vicki E., Xavier, Alexandre, Monif, Mastura, Min, Myintzu, Fabis-Pedrini, Marzena J., Buzzard, Katherine, Kalincik, Tomas, Kermode, Allan G., Taylor, Bruce, Hodgkinson, Suzanne, McCombe, Pamela, Osborne, Meaghan, Butzkueven, Helmut, Barnett, Michael, Lea, Rodney A. and Lechner-Scott, Jeannette (2024). DNA methylation discriminates between responder and non-responder status in a long-term study of cladribine tablet use in multiple sclerosis. Multiple Sclerosis Australia: Progress in MS Research Conference (MS), Perth, WA, Australia, 29 November - 1 December 2023. London, United Kingdom: Sage Publications.

DNA methylation discriminates between responder and non-responder status in a long-term study of cladribine tablet use in multiple sclerosis

2024

Conference Publication

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Sharmin, Sifat, Roos, Izanne, Simpson-Yap, Steve, Malpas, Charles, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Kermode, Allan, Butler, Ernest, Barnett, Michael, Hodgkinson, Suzanne, McCombe, Pamela, Taylor, Bruce, Slee, Mark, Macdonell, Richard, Garber, Justin, Shaw, Cameron, Shuey, Neil, Massey, Jennifer, Hardy, Todd, Parratt, John and Kalincik, Tomas (2024). The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Multiple Sclerosis Australia: Progress in MS Research Conference (MS), Perth, WA, Australia, 29 November - 1 December 2023. London, United Kingdom: Sage Publications.

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

2024

Conference Publication

Closing the gap in diagnosis of neuropathies and late-onset neurological disorders - a trans-Australia collaboration

Laing, N., Kennerson, M., Lamont, P., Vucic, S., Davis, M., Bryson-Richardson, R., Ravenscroft, G., Perez-Siles, G., Ghaoui, R., Narayanan, R., McCombe, P., Deveson, I., Bryen, S., Grosz, B., Johari, M., Rick, A., Folland, C., Scriba, C., Parmar, J. and Ellis, M. (2024). Closing the gap in diagnosis of neuropathies and late-onset neurological disorders - a trans-Australia collaboration. 29th International Congress of the World-Muscle-Society (WMS), Prague, Czech Republic, 8-12 October 2024. London, United Kingdom: Elsevier. doi: 10.1016/j.nmd.2024.07.328

Closing the gap in diagnosis of neuropathies and late-onset neurological disorders - a trans-Australia collaboration

2024

Conference Publication

Real-world Australian experience with Ofatumumab in the MSBase Registry

Barnett, Michael, van der Walt, Anneke, Butzkueven, Helmut, Kalincik, Tomas, Spelman, Tim, Kermode, Allan, Fabis-Pedrini, Marzena, Carroll, William M., Lechner-Scott, Jeannette, John, Nevin, Hodgkinson, Suzanne, McCombe, Pamela, Macdonell, Richard, Slee, Mark, Migocki, Margaret, Martel, Kate and Schmitt, Birte (2024). Real-world Australian experience with Ofatumumab in the MSBase Registry. 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 18-20 September 2024. London, United Kingdom: Sage Publications.

Real-world Australian experience with Ofatumumab in the MSBase Registry

2024

Conference Publication

Real-world experience with Cladribine (Mavenclad) in the MSBase registry

Butzkueven, Helmut, Spelman, Tim, Van der Walt, Anneke, Hodgkinson, Suzanne, Ozakbas, Serkan, Alroughani, Raed, Kalincik, Tomas, Eichau, Sara, Boz, Cavit, Buzzard, Katherine, Habek, Mario, John, Nevin, Kermode, Allan G., Foschi, Matteo, McCombe, Pamela, Gerlach, Oliver, Prevost, Julie, Meca-Lallana, Jose E., Lapointe, Emmanuelle and Jarvinen, Elina (2024). Real-world experience with Cladribine (Mavenclad) in the MSBase registry. 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 18-20 September 2024. London, United Kingdom: Sage Publications.

Real-world experience with Cladribine (Mavenclad) in the MSBase registry

2024

Conference Publication

Employing Novel Indirect Treatment Comparison Methodologies to Differentiate the Efficacy of Ofatumumab and Other High Efficacy Therapies versus Orally Administered Disease Modifying Therapies for Relapsing Multiple Sclerosis

Nelson, Morag, Butzkueven, Helmut, Van der Walt, Anneke, Broadley, Simon, Riley, Nicholas, Adlard, Nicholas, Merschhemke, Martin, Stoneman, Dee, McCombe, Pamela, Barnett, Michael, Walker, Rob, Samjoo, Imtiaz, Haltner, Anja and Drudge, Chris (2024). Employing Novel Indirect Treatment Comparison Methodologies to Differentiate the Efficacy of Ofatumumab and Other High Efficacy Therapies versus Orally Administered Disease Modifying Therapies for Relapsing Multiple Sclerosis. 16th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis, Bangkok, Thailand, 30 October - 2 November 2024. London, United Kingdom: Sage Publications.

Employing Novel Indirect Treatment Comparison Methodologies to Differentiate the Efficacy of Ofatumumab and Other High Efficacy Therapies versus Orally Administered Disease Modifying Therapies for Relapsing Multiple Sclerosis

2024

Conference Publication

Real-world Australian experience with Ofatumumab in the MSBase registry

Migocki, Margaret, Walt, Anneke Van der, Butzkueven, Helmut, Spelman, Tim, Kermode, Allan, Fabis-Pedrini, Marzena, Carroll, William M., Lechner-Scott, Jeannette, John, Nevin, Barnett, Michael, Hodgkinson, Suzanne, McCombe, Pamela, Kalincik, Tomas, Macdonell, Richard, Slee, Mark and Schmitt, Birte (2024). Real-world Australian experience with Ofatumumab in the MSBase registry. ANZAN Annual Scientific Meeting 2024, Adelaide, SA Australia, 21-24 May 2024. London, United Kingdom: BMJ Group. doi: 10.1136/bmjno-2024-anzan.127

Real-world Australian experience with Ofatumumab in the MSBase registry

2024

Conference Publication

Utilisation of high efficacy therapy for managing multiple sclerosis in Australia

McCombe, Pamela, Butzkueven, Helmut, Samjoo, Imtiaz, Barnett, Michael, Broadley, Simon, Walt, Anneke Van der, Merschhemke, Martin, Adlard, Nicholas, Burke, Naomi, Riley, Nicholas and Walker, Rob (2024). Utilisation of high efficacy therapy for managing multiple sclerosis in Australia. ANZAN Annual Scientific Meeting 2024, Adelaide, SA Australia, 21-24 May 2024. London, United Kingdom: BMJ Group. doi: 10.1136/bmjno-2024-anzan.23

Utilisation of high efficacy therapy for managing multiple sclerosis in Australia

2023

Conference Publication

Novel real world evidence from MSGo, a digital support program for secondary progressive multiple sclerosis patients in Australia using Siponimod

Hardy, Todd, Aouad, Patrick, Barnett, Michael, Blum, Stefan, Broadley, Simon, Carroll, William, Crimmins, Denis, Griffiths, Dayna, Hodgkinson, Suzanne, Lechner-Scott, Jeannette, Lee, Andrew, Malhotra, Ram, McCombe, Pamela, Parratt, John, Plummer, Christopher, Van der Walt, Anneke, Martel, Kate and Walker, Rob (2023). Novel real world evidence from MSGo, a digital support program for secondary progressive multiple sclerosis patients in Australia using Siponimod. PACTRIMS 2022: 12th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis, Singapore, Singapore, 24-26 November 2022. London, United Kingdom: Sage Publications.

Novel real world evidence from MSGo, a digital support program for secondary progressive multiple sclerosis patients in Australia using Siponimod

2022

Conference Publication

Comparison of the effectiveness of ocrelizumab vs interferon β, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis

Roos, Izanne, Sharmin, Sifat, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, Walt, Anneke van der, Butzkueven, Helmut, Butler, Ernest, MacDonell, Richard, McCombe, Pamela, Slee, Mark, Malpas, Charles and Kalincik, Tomas (2022). Comparison of the effectiveness of ocrelizumab vs interferon β, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis. ANZAN Annual Scientific Meeting 2022, Melbourne, VIC Australia, 10-13 May 2022. London, United Kingdom: BMJ. doi: 10.1136/bmjno-2022-anzan.26

Comparison of the effectiveness of ocrelizumab vs interferon β, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis

2022

Conference Publication

Latitude, UVR and multiple sclerosis severity

Vitkova, Marianna, Diouf, Ibrahima, Malpas, Charles, Barnett, Michael, Hodgkinson, Suzanne, Butler, Ernest, Slee, Mark, Taylor, Bruce, Butzkueven, Helmut, Lechner-Scott, Jeanette, McCombe, Pamela, Vucic, Steve, Macdonell, Richard, Shaw, Cameron and Kalincik, Tomas (2022). Latitude, UVR and multiple sclerosis severity. ANZAN Annual Scientific Meeting 2022, Melbourne, VIC Australia, 10-13 May 2022. London, United Kingdom: BMJ. doi: 10.1136/bmjno-2022-anzan.29

Latitude, UVR and multiple sclerosis severity

2021

Conference Publication

Real-world experience with cladribine tablets in the MSBase Registry (2942)

Butzkueven, Helmut, Spelman, Timothy, Hodgkinson, Suzanne, Kalincik, Tomas, Buzzard, Katherine, Skabina, Olga, Madueño, Sara Eichau, Ayuso, Guillermo Izquierdo, Van der Walt, Anneke, Grand-Maison, Francois, Butler, Ernest, Prevost, Julie, McCombe, Pamela, Oh, Jiwon, Macdonell, Richard, Lechner-Scott, Jeannette, Van Pesch, Vincent, Duquette, Pierre, Prat, Alexandre, Girard, Marc, Kermode, Allan and Fabris, Jessica (2021). Real-world experience with cladribine tablets in the MSBase Registry (2942). 2021 AAN 73rd Annual Meeting, Virtual, 17-22 April 2021. Philadelphia, PA USA: Wolters Kluwer Health. doi: 10.1212/wnl.96.15_supplement.2942

Real-world experience with cladribine tablets in the MSBase Registry (2942)

2021

Conference Publication

MRI patterns distinguish neuromyelitis optica spectrum disorder from multiple sclerosis

Clarke, Laura, Arnett, Simon, Bukhari, Wajih, Khalilidehkordi, Elham, Sanchez, Sofia Jimenez, O’Gorman, Cullen, Prain, Kerri, Woodhall, Mark, Silvestrini, Roger, Bundell, Christine, Abernethy, David, Bhuta, Sandeep, Blum, Stefan, Boggild, Mike, Boundy, Karyn, Brew, Bruce, Brownlee, Wallace, Butzkueven, Helmut, Carroll, William, Chen, Celia, Coulthard, Alan, Dale, Russell, Das, Chandi, Fabis-Pedrini, Marzena, Fulcher, David, Gillis, David, Hawke, Simon, Heard, Robert, Henderson, Andrew ... Broadley, Simon (2021). MRI patterns distinguish neuromyelitis optica spectrum disorder from multiple sclerosis. AAN 73rd Annual Meeting, Online, 17-22 April 2021. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.96.15_supplement.4128

MRI patterns distinguish neuromyelitis optica spectrum disorder from multiple sclerosis

2021

Conference Publication

Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)

Diouf, Ibrahima, Malpas, Charles, Horakova, Dana, Havrdova, Eva, Patti, Francesco, Shaygannejad, Vahid, Ozakbas, Serkan, Ayuso, Guillermo Izquierdo, Madueño, Sara Eichau, Zakaria, Magd, Onofrj, Marco, Lugaresi, Alessandra, Alroughani, Raed, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Terzi, Murat, Boz, Cavit, Grand’Maison, Francois, Hamdy, Sherif, Sola, Patrizia, Ferraro, Diana, Grammond, Pierre, Turkoglu, Recai, Butzkueven, Helmut, Yamout, Bassem, Altintas, Ayse, Van Pesch, Vincent, Maimone, Davide ... Kalincik, Tomas (2021). Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107). AAN 73rd Annual Meeting, Online, 17-22 April 2021. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.96.15_supplement.4107

Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)

2020

Conference Publication

Determinants of Therapeutic Lag in Multiple Sclerosis

Roos, Izanne, Leray, Emmanuelle, Frascoli, Federico, Casey, Romain, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Ayuso, Guillermo Izquierdo, Madueno, Sara Eichau, Patti, Francesco, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, Ozakbas, Serkan, Sola, Patrizia, Ferraro, Diana, Bergamaschi, Roberto, Cartechini, Elisabetta, Sa, Maria Jose, Boz, Cavit, Grand-Maison, Francois, Lechner-Scott, Jeannette, Terzi, Murat, Granella, Franco, Alroughani, Raed, Iuliano, Gerardo ... Kalincik, Tomas (2020). Determinants of Therapeutic Lag in Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

Determinants of Therapeutic Lag in Multiple Sclerosis

2020

Conference Publication

Real world safety of Alemtuzumab in the treatment of Multiple Sclerosis – Australian cohort study

Corbett, Joel, Blum, Stefan, Boggild, Mike, Broadley, Simon and McCombe, Pamela (2020). Real world safety of Alemtuzumab in the treatment of Multiple Sclerosis – Australian cohort study. 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.1499

Real world safety of Alemtuzumab in the treatment of Multiple Sclerosis – Australian cohort study

2020

Conference Publication

Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis

Kalincik, Tomas, Diouf, Ibrahima, Malpas, Charles, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Ayuso, Guillermo Izquierdo, Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Grand'Maison, Francois, Sola, Patrizia, Ferraro, Diana, Shaygannejad, Vahid, Alroughani, Raed, Hupperts, R. M. M., Terzi, Murat, Boz, Cavit, Lechner-Scott, Jeannette, Cartechini, Elisabetta, Van Pesch, Vincent, Iuliano, Gerardo, Granella, Franco, Bergamaschi, Roberto, Fernandez Bolanos, Ricardo ... Butzkueven, Helmut (2020). Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

Immunotherapies Improve Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis

2020

Conference Publication

Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 Years

Celius, Elisabeth G., Oh, Jiwon, Achiron, Anat, Compston, D Alastair S., Devonshire, Virginia, Hellwig, Kerstin, Hutton, George J., McCombe, Pamela, Moore, Marie, Simm, Renata Faria, Sousa, Livia, Vincent, Stephen G., Chung, Luke, Daizadeh, Nadia, Mitchell, Colin and Rog, David (2020). Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 Years. 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.169

Postpartum Relapse After First On-Study Pregnancy in RRMS Patients Treated With Alemtuzumab in the Phase 2 and 3 Clinical Development Program Over 8 Years

2020

Conference Publication

Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis

Sharmin, Sifat, Bovis, Francesca, Malpas, Charles, Horakova, Dana, Havrdova, Eva, Ayuso, Guillermo Izquierdo, Eichau, Sara, Trojano, Maria, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Hupperts, R. M. M., Alroughani, Raed, Boz, Cavit, Shaygannejad, Vijay, Van Pesch, Vincent, Kappos, Ludwig, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Turkoglu, Recai, Solaro, Claudio, Ramo-Tello, Cristina ... Kalincik, Tomas (2020). Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis. Annual Meeting of the American Academy of Neurology, Toronto, Canada, 25 April-1 May 2020. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis

2020

Conference Publication

Cladribine: a multicentre LOng-term efficacy Biomarker Australian Study (CLOBAS)

Maltby, Vicki, Lydon, Amanda, Monif, Mastura, Kilpatrick, Trevor, Butzkueven, Helmut, Taylor, Bruce, McCombe, Pamela, Hodgkinson, Suzanne, Fabis-Pedrini, Marzena, Kermode, Allan, Barnett, Michael, Kalincik, Tomas and Lechner-Scott, Jeannette (2020). Cladribine: a multicentre LOng-term efficacy Biomarker Australian Study (CLOBAS). 2020 AAN Science Highlights, Online, 14 April 2020. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.94.15_supplement.5285

Cladribine: a multicentre LOng-term efficacy Biomarker Australian Study (CLOBAS)